CPC A61K 35/17 (2013.01) [A61K 39/0011 (2013.01); A61K 39/00117 (2018.08); A61K 39/00118 (2018.08); A61K 39/001104 (2018.08); A61K 39/001106 (2018.08); A61K 39/001109 (2018.08); A61K 39/001112 (2018.08); A61K 39/001113 (2018.08); A61K 39/001119 (2018.08); A61K 39/001124 (2018.08); A61K 39/001153 (2018.08); A61K 39/001156 (2018.08); A61K 39/001157 (2018.08); A61K 39/001161 (2018.08); A61K 39/001162 (2018.08); A61K 39/001166 (2018.08); A61K 39/001168 (2018.08); A61K 39/001171 (2018.08); A61K 39/001176 (2018.08); A61K 39/001181 (2018.08); A61K 39/001182 (2018.08); A61K 39/001184 (2018.08); A61K 39/001186 (2018.08); A61K 39/001188 (2018.08); A61K 39/001189 (2018.08); A61K 39/001191 (2018.08); A61K 39/001192 (2018.08); A61K 39/001193 (2018.08); A61K 39/001194 (2018.08); A61K 39/001195 (2018.08); A61K 39/001197 (2018.08); C07K 14/7051 (2013.01); C12N 5/0636 (2013.01); C12N 5/0638 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/5158 (2013.01); A61K 2039/572 (2013.01); C12N 2501/2302 (2013.01); C12N 2501/2307 (2013.01); C12N 2501/2315 (2013.01); C12N 2501/727 (2013.01); C12N 2506/11 (2013.01)] | 12 Claims |
1. A method for culturing T cells for a T cell therapy while delaying or inhibiting maturation or differentiation of the T cells, comprising:
contacting, in a culture medium, one or more T cells with exogenous Interleukin-7 (IL-7) and exogenous Interleukin-15 (IL-15) in the absence of exogenous Interleukin-2 (IL-2),
wherein the one or more T cells comprise CD4+ T cells, and the contacting is for 1 day to 10 days such that the CD4+ T cells, following such contacting, comprise a higher percentage of naive T cells and central memory T (Tcm) cells as compared to when the CD4+ T cells are contacted with exogenous IL-2 in the absence of exogenous IL-7 and exogenous IL-15.
|